AnimaBiotech
Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation
mRNA translation modulators -
a novel target space
Tremendous opportunities - unique advantages
protein translation
novel target space
Our Approach
Our platform identifies small molecules that selectively modulate the mRNA translation of target proteins. The novel target space enables the discovery of drugs that can either decrease or increase the production of proteins in a tissue selective manner.
Specifically decrease or increase the mRNA translation of target proteins
Tissue Selectivity
Tissues use different regulatory proteins for the same mRNA allowing for selective Translation Control
Product Pipeline
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors), Huntington’s Disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions).
Pharma Collaborations
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact [email protected].
17 Scientific Collaborations
14 Publications
-
A heterogeneous tRNA granule structure exhibiting rapid, bi-directional neuritictransport
Eur J Cell Biol (2018) ; 97 : 168-179. -
Monitoring protein synthesis in single live cancer cells
Integr Biol (2016); 8 :645-53 -
DSCR1 is required for both axonal growth cone extension and steering
J Cell Biol. 2016; 23;213(4):451-62. -
In vivo single-RNA tracking shows that most tRNA diffuses freely in live bacteria
Nucleic Acid Res. (2017); 45 :926-937
Coverage
News & Events
-
2nd Annual RNA as a Drug Target Conference
When: Sep. 16th, 2020 - Sep. 18th, 2020
Anima Biotech has been invited to present and participate on an expert panel during the Cambridge Healthtech Institute’s 2nd Annual RNA as a Drug Target Conference, between Sep. 16-17, 2020. Yochi Slonim, Co-founder and CEO of Anima Biotech, will be giving a presentation during the RNA as a Drug Target session, titled, “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators, on Thursday, Sep. 17 at 10:15 a.m. ET. As part of the same session, Dr. Iris Alroy, VP of R&D, will participate on an expert wrap-up panel discussion on Thursday, Sep. 17 at 11:35 a.m. ET.
-
Cambridge Healthtech Institute’s Inaugural RNA as a Small Molecule Target Symposium
When: Aug. 28th, 2020
Anima Biotech has been invited to give an overview of its Translation Control Therapeutics platform at the Inaugural RNA as a Small Molecule Target Symposium. Co-founder and CEO, Yochi Slonim and vice president of research and development Dr. Iris Alroy will jointly present a talk titled “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators,” on Friday, Aug.
-
ChinaBio Partnering Forum
When: Aug. 25th, 2020 - Aug. 27th, 2020
Anima Biotech’s co-founder and CEO, Yochi Slonim, has been invited to present about its business, technology and partnering strategies during the ChinaBio Partnering Forum 2020.
The ChinaBio Partnering Forum is the premier life science partnering event in China. The event attracts biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.